-
BioPharma Dive – AI / Data6 months agoJ&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug,...
-
BioPharma Dive – AI / Data6 months agoAspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.
-
BioPharma Dive – AI / Data6 months agoCrossbow raises $77M for new cancer immunotherapies
Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.
Helixgate Featured8 hours ago
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
Helixgate Featured8 hours ago
Deep dive: Psychedelics back on FDA’s doorstep
Clinical Trials & Development8 hours ago
‘Patients are not a renewable resource’: Rethinking rare disease R&D
Fierce Biotech6 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago
